Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems Nets $2.2M in Private Placement

WASHINGTON, DC (GenomeWeb News) – Australian molecular diagnostics developer Proteome Systems has closed a private placement of AUD$2.5 million (US$2.2 million), the company said today.
Proteome Systems will issue 23,809,524 shares at AUD$0.105 per share to participants in the funding including Oppenheimer Funds and other US and Australian investors.
The Sydney-based firm said it will use the money to maintain development timelines for its two lead programs including a rapid point-of-care test for tuberculosis and an on-site test used to determine the quality of wheat, which will be used to help determine pricing.
The placement is being arranged by Foster Stockbroking, and the new shares will be ranked equal to the company’s ordinary shares.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.